# A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma

> **NCT01632228** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 135 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Onartuzumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01632228
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-29
- **Primary completion:** 2016-01-21
- **Final completion:** 2016-01-21
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2018-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01632228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01632228, "A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01632228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*